Skip to main content

Table 2 Dose modification of Irinotecan and 5-fluorouracil (5-FU) (N = 89)

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

 

Dose Level

Dose (mg/m2)

N

%

Duration until modification (days)

 

Median

Range

Irinotecan

0

180

52

58.4

-

-

 

−1

150

37

41.6

33.0

(14–448)

 

−2

125

12

13.5

76.5

(14–146)

 

−3

100

3

3.4

112.0

(47–181)

5-FU (bolus/infusion)*

0

400/2,400

55

61.8

-

-

 

−1

400/2,000

34

38.2

47.5

(14–448)

 

−2

0/1,600

9

10.1

82.0

(33–301)

  1. *No patient had the dose of only bolus or infusion of 5-FU reduced.